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Abstract
Introduction: Angiopoietin-1 (Angpt1), the natural agonist ligand for the endothelial Tie2 receptor, is a non-
redundant endothelial survival and vascular stabilization factor that reduces endothelial permeability and inhibits
leukocyte-endothelium interactions. Here we evaluate the efficacy of a novel polyethylene glycol (PEG)-clustered
Tie2 agonist peptide, vasculotide (VT), to protect against vascular leakage and mortality in a murine model of
polymicrobial abdominal sepsis.
Methods: Polymicrobial abdominal sepsis in C57BL6 mice was induced by cecal-ligation-and-puncture (CLP). Mice
were treated with different dosages of VT or equal volume of phosphate-buffered saline (PBS). Sham-operated
animals served as time-matched controls.
Results: Systemic administration of VT induced long-lasting Tie2 activation in vivo. VT protected against sepsis-
induced endothelial barrier dysfunction, as evidenced by attenuation of vascular leakage and leukocyte
transmigration into the peritoneal cavity. Histological analysis revealed that VT treatment ameliorated leukocyte
infiltration in kidneys of septic mice, probably due to reduced endothelial adhesion molecule expression. VT-driven
effects were associated with significantly improved organ function and reduced circulating cytokine levels. The
endothelial-specific action of VT was supported by additional in vitro studies showing no effect of VT on either
cytokine release from isolated peritoneal macrophages, or migratory capacity of isolated neutrophils. Finally,
administration of VT pre-CLP (hazard ratio 0.39 [95% confidence interval 0.19-0.81] P < 0.001) and post-CLP reduced
mortality in septic mice (HR 0.22 [95% CI 0.06-0.83] P < 0.05).
Conclusions: We provide proof of principle in support of the efficacious use of PEGylated VT, a drug-like Tie2
receptor agonist, to counteract microvascular endothelial barrier dysfunction and reduce mortality in a clinically
relevant murine sepsis model. Further studies are needed to pave the road for clinical application of this
therapeutic concept.
Introduction
In 1995/1996, Sato and colleagues [1] and Davis and col-
leagues [2] discovered Tie2 and its agonist ligand angio-
poietin-1 (Angpt1) as the second class of vascular-
specific receptor tyrosine kinases; the first was the vascu-
lar endothelial growth factor (VEGF)/VEGF receptor sys-
tem. Studies in Angpt1
-/- and Tie2
-/- knockout mice,
which die in utero owing to severe vascular remodeling,
convincingly demonstrated the importance of operational
Angpt1/Tie2 signaling for developmental angiogenesis
[1,3]. Besides having a role for vascular integrity in grow-
ing mice, Angpt1 was subsequently identified as a potent
anti-permeability factor that protected the vasculature of
adult mice from plasma leakage induced by VEGF and
other inflammatory stimuli [4]. Given the absence of
redundant systems to bypass the function of Angpt1/
Tie2, it was speculated early that excess Angpt1 effec-
tively abolishes microvascular leakage in experimental
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hypothesis by demonstrating that either acute adminis-
tration of recombinant Angpt1 protein or gene transfer
of Angpt1 prevented capillary leakage, protected against
subsequent acute kidney injury (AKI) and acute lung
injury (ALI), and improved survival in Gram-negative
murine endotoxemia [5-11].
During human endotoxemia and sepsis, circulating
Angpt1 levels remain unchanged or even decrease,
whereas the endogenous context-specific Tie-2 antago-
nist, angiopoietin-2 (Angpt2), is rapidly released by the
activated endothelium and disrupts the constitutive
Angpt1/Tie2 signaling by preventing Angpt1 from bind-
ing to the receptor [12-19].
We and others have shown that Angpt2 levels in plasma
from critically ill patients with sepsis correlate with the
extent of pulmonary vascular leakage in ALI [19], increase
with the severity of AKI [16], and independently predict
mortality in the intensive care unit [14,16,20-22]. Of note,
local or systemic injection of recombinant Angpt2 in
otherwise-healthy mice is sufficient to provoke tissue
edema or pulmonary vascular leakage, respectively [23,24].
Consistent with these observations, agents that acti-
vate the endothelial-specific Tie2 receptor pathway and
sufficiently protect against capillary leakage, vascular
inflammation, and subsequent multiple-organ damage
are highly desirable for the treatment of patients with
sepsis. However, neither gene therapy (with Angpt1) nor
the administration of large doses of recombinant
Angpt1 protein is feasible in clinical routine [6].
Recently, Tournaire and colleagues [25] described the
discovery of a short synthetic peptide (HHHRHSF) that
binds with high affinity to the extracellular portion of the
Tie2 receptor but lacks the capacity to displace either
Angpt1 or Angpt2. Using this peptide clustered as a tetra-
mer by way of avidin/biotin, Van Slyke and colleagues [26]
demonstrated that Tie2 could be activated in a manner
analogous to Angpt1. Subsequently, this proof-of-principle
compound, termed vasculotide (VT), was reengineered
into a more pharmaceutically amenable preparation that
excludes the avidin/biotin complex in favor of a tetrameric
polyethylene glycol (PEG) scaffold (Additional file 1).
We hypothesized that systemic administration of PEGy-
lated VT would activate Tie2 in animals, protect against
vascular leakage and tissue injury, and improve survival in
a murine cecal ligation and puncture (CLP) model of poly-
microbial sepsis. We performed studies in mice, resident
peritoneal macrophages (PMs), and isolated bone marrow-
derived neutrophils to test this hypothesis.
Materials and methods
Synthesis, purification, and validation of vasculotide
Peptide NH2-CHHHRHSF-COOH (GenScript USA Inc.,
Piscataway, NJ, USA) was reacted with four-armed PEG
(polydisperse, average molecular weight of 10 kDa)
(Sunbright PTE-100MA; NOF Corporation, Tokyo,
Japan) in a 12:1 molar ratio. Covalent attachment of the
peptide to the activated maleimide groups took place in
p h o s p h a t e - b u f f e r e ds a l i n e( P B S ) ,p H6 . 4 ,a tr o o mt e m -
perature with agitation for 4 hours. Products were puri-
fied by way of dialysis (Slide-A-Lyzer, 7000 Da, MWCO;
Pierce Biotechnology, now part of Thermo Fisher Scien-
tific Inc., Rockford, IL, USA) at 4°C with stirring. Pro-
ducts were first dialyzed against PBS at pH 7.4 (two
exchanges, 300X volume, 3 hours each) and then dou-
ble-distilled water (eight exchanges, 300X volume, 6
hours each). Dialyzed products were then frozen, lyophi-
lized, and weighed to calculate product yield. Validation
of VT was assessed by MALDI TOF (matrix-assisted
laser desorption/ionization time-of-flight mass spectro-
meter) to determine the potential presence of free pep-
tide impurities and to measure the molecular size
distribution of the final product (efficiency of
conjugation).
In vivo animal studies
All procedures were approved by the local committee
for care and use of laboratory animals (Lower Saxony
Office for Consumer Protection and Food Safety) and
were performed in accordance with international guide-
lines on animal experimentation. Eight- to 10-week-old
male C57BL6 mice (20 to 25 g) were obtained from
Charles River Laboratories (Sulzfeld, Germany). Mice
were maintained on mouse chow and tap water ad libi-
tum in a temperature-controlled chamber at 24°C with a
12:12-hour light-dark cycle. Polymicrobial sepsis in mice
was induced by CLP. In brief, mice were anesthetized
with isofluorane (induction of 3%, maintenance of 1.5%,
and oxygen flow of 3 L/minute), and a 1-cm ventral
midline abdominal incision was made. The cecum was
then exposed, ligated with 4-0 silk sutures just distal to
the ileocecal valve (comprising 70% of the cecum and
sparing the cecal vessels) to avoid intestinal obstruction,
and punctured through with a 24-gauge needle. The
punctured cecum was gently squeezed to expel a 1- to
2-mm droplet of fecal material and returned to the
abdominal cavity. The incision was then closed in layers
with 4-0 surgical sutures. Mice were fluid-resuscitated
with prewarmed normal saline (500 μL) intraperitoneally
(i.p.) immediately after the procedure. Sham animals
underwent the same procedure except for CLP. All
experiments were carried out at the same time of day.
Survival analysis
Mice were pretreated i.p. with different dosages (50, 200,
or 500 ng) of VT or PBS at 16 hours and 1 hour prior
to CLP or sham surgery and at 24 hours and 48 hours
afterward. To test whether delayed administration of VT
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of mice was subjected to CLP first and then treated
with 200 ng of VT or PBS i.p. at 2, 24, and 48 hours
after CLP surgery. Survival time was recorded daily up
to 14 days after CLP or sham surgery.
Short-term experiments: peritoneal lavage and Evans blue
permeability assay
In short-term experiments, mice were pretreated i.p.
with 200 ng of VT or PBS at 16 hours and 1 hour prior
to surgery. Immediately after surgery, 0.25% wt/vol
Evans blue dye (200 μL) was injected intravenously.
Evans blue dye avidly binds to serum albumin and
therefore can be used as a tracer for macromolecule flux
across the microvasculature. At 18 hours after CLP or
sham operation, mice were anesthetized with isofluorane
for blood sampling. Subsequently, animals were sacri-
ficed and peritoneal lavage (PL) was performed with 3
mL of PBS. The volume of the collected PL was mea-
sured in each sample, and the total cell count was
assessed with a hemocytometer (Neubauer Zählkammer,
Gehrden, Germany). For quantification of polymorpho-
nuclear neutrophil (PMN) accumulation, differential cell
counts were performed on cytospins (10 minutes at 55g)
stained with hematoxylin and eosin. PL fluids were cen-
trifuged at 500g for 5 minutes to pellet cells, and cell-
free supernatants were frozen at -70°C for subsequent
measurement of proinflammatory mediators. The con-
centration of Evans blue dye in appropriate dilutions of
serum and PL fluids was measured spectrophotometri-
cally at 620 nm. The following formula was used to cor-
rect the optical densities for contamination with heme
pigments: E620 (corrected) =E 620 (raw) -( E 405 (raw) × 0.014).
Plasma exudation was quantitated as the ratio of extinc-
tion in PL fluid to extinction in plasma.
Blood and tissue sampling
Mice were anesthetized with isofluorane for blood sam-
pling and subsequently sacrificed for tissue sampling at
18 hours after CLP or sham surgery (n = 10 per group).
Blood samples were obtained from the cavernous sinus
by means of a capillary. Kidneys were removed and
either fixed for 20 hours in 3.75% paraformaldehyde in
Sörensen’s phosphate buffer and embedded in paraffin
for histologic examination or snap-frozen in isopentane
(-40°C) for cryostat sectioning.
Clinical chemistry
Serum level of creatinine and urea and the activities of
aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were measured by an automated
method and an Olympus AU 400 analyzer (Beckman
Coulter Inc., Krefeld, Germany).
Cytokine detection in serum and peritoneal lavage
samples
Serum levels of the proinflammatory cytokines tumor
necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and
macrophage chemoattractant protein-1 (MCP-1) were
quantified by bead-based flow cytometry assay (CBA
Kit; BD Biosciences, Heidelberg, Germany) in accor-
dance with the instructions of the manufacturer. The
concentrations of two major neutrophil chemoattrac-
tants [27], macrophage inflammatory protein-2 (MIP-2)
and keratinocyte chemoattractant (KC), in serum and
PL fluids were measured with the respective specific
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems, Wiesbaden, Germany) in accordance with the
instructions of the manufacturer.
Immunofluorescence
Immunofluorescence was performed on ice-cold acet-
one-fixed cryosections (6 μm) by using the following
primary antibodies: rat anti-mouse intercellular adhesion
molecule-1 (ICAM-1) (or CD54, clone KAT-1; AbD Ser-
otec, Oxford, UK), rat anti-mouse vascular cell adhesion
molecule-1 (VCAM-1) (or CD106, clone MVCAM.A;
AbD Serotec), rat anti-mouse Gr-1-positive neutrophils
(clone 7/4; AbD Serotec), and rabbit anti-human/mouse
phosphorylated Tie2 (pTie2, Y1102; R&D Systems,
Oxon, UK). Non-specific binding sites were blocked
with 10% normal donkey serum (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA, USA) for 30
minutes. Thereafter, sections were incubated with the
primary antibody for 1 hour. All incubations were per-
formed in a humid chamber at room temperature. For
fluorescent visualization of bound primary antibodies,
sections were further incubated with Cy3-conjugated
secondary antibodies (Jackson ImmunoResearch Labora-
tories, Inc.) for 1 hour in the dark. For negative controls,
the staining procedure was performed as described with-
out the primary antibodies. Specimens were analyzed
with a Zeiss Axioplan-2 imaging microscope and the
digital image-processing program AxioVision 4.6 (Zeiss,
Jena, Germany).
Analysis of infiltrating neu t r o p h i l sw a sd o n eb ye n u -
merating Gr-1-positve cells in kidney tissue sections
(n = 7 to 10 per group). Data are expressed as the mean
number of 20 randomly chosen, non-overlapping fields
per section. Analysis of pTie2 expression in renal vascu-
lature was done by semiquantitative scoring as follows:
0 = no, 1 = very weak, 2 = weak, 3 = moderate, 4 =
strong, and 5 = very strong expression. Data are
expressed as the mean the mean score of 20 randomly
chosen, non-overlapping fields per section. Analysis of
adhesion molecule expression in specific vascular sec-
tions (that is, glomeruli, arteries, and peritubular
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l o w s :0=n o ,1=v e r yw e a k ,2=w e a k ,3=m o d e r a t e ,4
=s t r o n g ,a n d5=v e r ys t r o n ge x p r e s s i o n .D a t aa r e
expressed as the mean score of 40 glomeruli or 20 ran-
domly chosen, non-overlapping interstitial fields (for
arteries and peritubular capillaries) per section. The
investigator had no knowledge of the treatment group
assignment.
Tie2 immunoprecipitation
For determination of Tie2 phosphorylation, kidneys
from healthy mice (n = 3 per group) were harvested at
16 and 34 hours after VT pretreatment (200 ng of VT i.
p. at 0 and 16 hours). Mice (n = 3) injected with control
buffer (PBS) only served as baseline controls (0 hours).
Kidney tissue from each animal was homogenized in
RIPA lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS,
2m Ms o d i u mo r t h o v a n a d a t e ,a nd protease inhibitors).
Lysates were then centrifuged at 14,000g for 15 minutes
at 4°C. The supernatants were aliquoted on the basis of
the protein concentration measured by using a BCA
(bicinchoninic acid) protein assay (Thermo Fisher Scien-
tific Inc.) and stored at -80°C. Tie2 was immunoprecipi-
tated from the supernatant by using 2 to 4 μgo fa n t i -
Tie2 antibody C20 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) that had been precoupled to 25
μL of protein-A-Sepharose (GE Healthcare, Little Chal-
font, Buckinghamshire, UK) [28].
Tie2 immunoblotting
Proteins were resolved on a 7.5% polyacrylamide gel and
transferred to PVDF (polyvinylidene fluoride) (PerkinEl-
mer Life and Analytical Sciences, Inc., Waltham, MA,
USA) membranes. The membranes were blocked for 1
hour at room temperature in 5% bovine serum albumin
(BSA) prior to detecting phosphotyrosine or in 5% non-
fat dry milk for detecting total Tie2. The membranes
were incubated with 1 μg/mL anti-phosphotyrosine anti-
body 4G10 (Upstate/Millipore, Billerica, MA, USA) or
0.5 μg/mL anti-Tie2 monoclonal antibody (Millipore).
Proteins were visualized by using secondary antibodies
conjugated to HRP (horseradish peroxidase) (Bio-Rad,
Mississauga, ON, Canada) followed by enhanced chemi-
luminescence [28].
Functional analysis of resident peritoneal macrophages in
vitro
Mouse resident PMs were obtained from untreated
wild-type mice by PL by using 10 mL of PBS (2 × 5
mL). The cells were centrifuged at 300g for 10 minutes
at 4°C, the supernatants were decanted, and the cell pel-
lets were washed twice with RPMI 1640 medium. Cells
were resuspended in RPMI 1640 medium supplemented
with 10% fetal calf serum (FCS) and plated in 24-well
plastic culture plates (Corning Incorporated, Corning,
NY, USA) to achieve a final concentration of 1.5 × 10
6
cells/mL per well. The plates were incubated for 2 hours
at 37°C, 5% CO2, and 95% humidity to allow macro-
phage adherence. Non-adherent cells were removed by
vigorous washing with RPMI 1640 medium. Primary
murine PMs were starved for 24 hours in 1% FCS/RPMI
1640 medium in 24-well plates and preincubated or not
with 25 or 100 ng/mL VT for 1 hour and then stimu-
lated with 10 ng/mL lipopolysaccharides (LPSs) (O111:
B4, Sigma-Aldrich, Munich, Germany) for 4 hours. In
some experiments, PMs were preincubated with a molar
excess (5 μg/mL) of a recombinant human Tie2/Fc chi-
mera (R&D Systems, Wiesbaden, Germany) for 30 min-
utes prior to the addition of VT. The medium was
collected from cultured PMs with or without the treat-
ments mentioned above and centrifuged. Production of
MIP-2 and KC was examined in supernatants by using
specific ELISA kits (R&D Systems) in accordance with
the instructions of the manufacturer.
Chemotaxis assay in vitro
Wild-type murine bone marrow cells were suspended at
7.5 × 10
6 cells per mL RPMI 1640 medium with 0.25%
BSA (Sigma-Aldrich). Neutrophils in the cell suspension
were determined by means of a Vet ABC hematology ana-
lyzer (scil animal care company, Gurnee, IL, USA) to be in
the range of 64% to 68% of total cells. Next, 100 μL of the
cell suspension was placed into the upper well insert of a
6.5-mm diameter, 3-μm pore polycarbonate Transwell
chemotaxis chamber (Costar Corning, Corning, NY, USA),
and the bottom well was filled with 600 μLo fR P M I1 6 4 0 /
0.25% BSA (medium control). PMNs were preincubated
with a different concentration of VT for 1 hour and there-
after used for Transwell migration assays toward an opti-
mal dose (50 ng/mL) of recombinant human C5a (rhC5a;
Sigma-Aldrich) or toward PL pools (diluted 1:2 with RPMI
1 6 4 0 / 0 . 5 %B S A )o b t a i n e da t1 8h o u r sa f t e rC L Ps u r g e r y .
The chambers were incubated at 37°C and 5% CO2 for 2
hours. Next, 50 μL of 70 mM EDTA (ethylenediaminete-
traacetic acid) solution was added to the bottom chambers
to release adherent cells from the lower surface of the
membrane and from the bottom of the well. Plates were
further incubated for 30 minutes at 4°C, inserts were
removed, and the transmigrated neutrophils were vigor-
ously suspended and counted by using a Vet ABC hema-
tology analyzer. Migration of PMNs from the insert to the
bottom well was quantified as the percentage of total
PMNs loaded into the upper chamber.
Statistical analysis
Data are presented as mean ± standard error of mean.
Multiple comparisons were analyzed for significant
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with the Tukey as a post hoc test for multiple compari-
sons. Kaplan-Meier plots were used to illustrate survival
between treatment groups, and statistical assessment
was performed by the log-rank test. Animals still alive at
14 days after CLP were censored at day 14. All tests
were two-sided, and significance was accepted at a P
value of less than 0.05. GraphPad Prism version 5.02
(GraphPad Prism Software Inc., San Diego, CA, USA)
was used for data analysis and figure preparation.
Results
Vasculotide induces Tie2 posphorylation in vivo
Having verified that VT induces Tie2 phosphorylation
(that is, activation) in vitro in previous work [26], we
initially tested whether VT can also induce Tie2 activa-
tion in vivo. We performed immunoprecipitation for
Tie2 and consecutive immunoblot for phospho-tyrosine
(pY) in kidney homogenates obtained from healthy
C57BL6 mice treated with 200 ng of VT i.p. As
expected, VT treatment induced a long-lasting increase
of the phosporylated fraction of Tie2 in vivo (Additional
file 1).
Vasculotide prevents capillary leakage and neutrophil
transmigration in vivo
To assess the putative anti-permeability and anti-trans-
migratory capacity of VT in vivo, we quantified the
extravasation of Evans blue dye and the transmigration
of leukocytes into the abdominal cavity. After initial
dose-ranging studies, C57BL6 mice received 200 ng of
VT (or an equal volume of PBS) i.p. at 16 hours and 1
hour prior to CLP or sham surgery, respectively. Com-
pared with sham surgery, CLP produced a significant
increase in dye extravasation at 18 hours after the pro-
cedure. Of note, sepsis-induced peritoneal hyperperme-
ability was substantially reduced by pretreatment with
VT (Figure 1A). Consistent with the scarcity of early
ALI in the CLP model used here, Evans blue dye con-
tent was not different in bronchoalveolar lavage fluid
samples from CLP, CLP plus VT, or sham animals (data
not shown). At 18 hours after CLP, the total
Figure 1 Vasculotide (VT) prevents capillary leakage and neutrophil transmigration in vivo. Mice were pretreated with VT (200 ng
intraperitoneally) or phosphate-buffered saline (PBS) at 16 hours and 1 hour prior to cecal ligation and puncture (CLP). Sham animals were
pretreated with PBS at 16 hours and 1 hour prior to surgery. Immediately after surgery, Evans blue dye was injected intravenously. (A) Evans
blue dye content in peritoneal lavage (PL) fluid at 18 hours after CLP or sham operation. (B) White blood cell (WBC) counts and (C, D)
differential cell counts from PL samples at 18 hours after CLP or sham operation. Data are expressed as mean ± standard error of the mean
(n = 7 to 10 mice per group). *P < 0.05; **P < 0.01; **P < 0.001. n.s., not significant; OD, optical density; PMN, polymorphonuclear neutrophil.
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approximately fivefold over sham controls, and this was
attributable mainly to an increase in PMNs (~86%)
(Figure 1B, C). VT pretreatment significantly blocked
sepsis-induced PMN transmigration, as evidenced by
reduced total cell counts and PMNs in the PL fluid. In
addition, macrophage counts in the PL fluid were signif-
icantly reduced by VT treatment (Figure 1D).
Vasculotide ameliorates endothelial adhesion molecule
expression and leukocyte influx in septic kidneys
Leukocyte trafficking across the vascular endothelium is
critically dependent on endothelial adhesion molecules,
such as ICAM-1, VCAM-1, and E-selectin [29,30].
Therefore, we investigated whether VT ameliorates
upregulation of endothelial adhesion molecules and sub-
sequent leukocyte influx in vital organs, such as the kid-
ney. We used immunofluorescence staining to localize
and semiquantify the protein expression of ICAM-1 and
VCAM-1 among specific vascular sections within the
renal vasculature. CLP-induced upregulation of ICAM-1
in glomeruli and peritubular capillaries was significantly
reduced in VT-treated mice compared with buffer-trea-
ted controls at 18 hours after CLP (Figure 2A). CLP-
induced upregulation of VCAM-1 expression did not
occur in the glomerular endothelium (data not shown)
but was present in arteries and, to a lesser extent, in
peritubular capillaries. In contrast to septic controls, VT
significantly reduced arterial VCAM-1 expression but
did not ameliorate upregulation of VCAM-1 in peritub-
ular capillaries after CLP (Figure 2B). Despite repeated
attempts, we were unable to stain for E-selectin and to
quantify ICAM-1 or VCAM-1 expression by Western
blotting. As shown by semiquantitative analysis, VT
treatment resulted in considerable attenuation of leuko-
cyte influx into septic kidneys at 18 hours after CLP
(Figure 2C). Consistent with immunofluorescence data,
VT-treated mice were largely protected from acute liver
injury (Additional file 2) and AKI compared with buffer-
treated CLP mice at 18 hours after CLP induction, as
evidenced by significantly lower serum creatinine and
urea levels (Figure 2D).
Vasculotide augments Tie2 signaling in vivo
We recently reported a reduction of Tie2 transcript and
protein abundance in septic kidneys, which is propor-
tional to the severity of the CLP model used [6]. To
explore signaling changes induced by CLP and VT, we
used immunofluorescence to detect and quantify pTie2
(that is, activated Tie2) in kidneys from septic and
sham-treated mice. CLP resulted in considerable
attenuation of pTie2 abundance (that is, deactivation)
compared with sham operation. VT pretreatment fully
restored pTie2 staining to control intensity (Figure 3).
Together, these results suggest that the decreased Tie2
protein abundance induced by CLP is overcome by
increased activation of the remaining Tie2 molecules
when VT is given.
Vasculotide suppresses CLP-induced upregulation of
proinflammatory and chemotactic cytokines
T h em a g n i t u d eo ft h ei n f l a m m a t o r yr e s p o n s ei sa l s o
dependent on local and systemic production of proin-
flammatory as well as chemotactic mediators: early-
response cytokines, such as TNF-a and IL-6, induce
endothelial activation and enhance endothelial adhesion
molecule expression, whereas chemokines, especially
KC, MIP-2, and MCP-1, play a central role in inflamma-
tory cell chemotaxis by attracting and stimulating speci-
fic subsets of leukocytes. As expected, both cytokines
and chemokines were significantly elevated in serum
and PL fluid at 18 hours after CLP (Figure 4A). Pre-
treatment with 200 ng of VT caused a significant reduc-
tion in serum and PL fluid levels in each of the
aforementioned cytokines-except for serum TNF-a,
which, however, was not affected by VT-at 18 hours
(Figure 4A).
Vasculotide affects neither cytokine release from resident
peritoneal macrophages nor migratory capacity of
polymorphonuclear neutrophils in vitro
Gu and colleagues [31] recently reported that Tie2 acti-
vation by Angpt1 is sufficient to block LPS-induced
cytokine production in a macrophage cell line. Tie2
expression in resident PMs was confirmed at the protein
level by ELISA and Western blotting (data not shown).
Next, we tested whether VT interferes with the LPS-
induced release of MIP-2 and KC from resident PMs in
vitro. Stimulation of PMs isolated from healthy C57BL6
mice with LPS resulted in a strong release of levels of
both KC and MIP-2. However, preincubation of the
cells with a different concentration of VT was not able
to change this response (Figure 4B), indicating that the
attenuation of PMN recruitment after VT treatment in
vivo is not attributable to changes in the net release of
cytokines from activated macrophages.
In addition, we tested whether VT attenuates PMN
migration in vitro in a direct fashion. Migratory capacity
of isolated PMNs from healthy C57BL6 mice elicited
with PL fluid or rhC5a was assessed by Transwell migra-
tion assay. Pooled PL fluid from PBS-treated septic mice
obtained at 18 hours after CLP elicited a 10-fold
increase in PMN migration in comparison with PL fluid
from sham-treated controls. This response was signifi-
cantly less pronounced (~40%) if PL fluid from VT-trea-
ted septic mice was used and reached only sixfold over
controls in PMN migration (Additional file 3). Interest-
ingly, preincubation of PMNs with a different
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Page 6 of 14Figure 2 Vasculotide (VT) ameliorates acute kidney injury. Mice were pretreated with VT (200 ng intraperitoneally) or phosphate-buffered
saline at 16 hours and 1 hour prior to cecal ligation and puncture (CLP) or sham surgery, respectively. Kidney tissues were harvested at 18 hours
after CLP or sham treatment. (A) Immunofluorescence study of intercellular adhesion molecule-1 (ICAM-1) and (B) vascular cell adhesion
molecule-1 (VCAM-1) protein expression (red) among specific sections within the renal vasculature (that is, glomeruli [400 ×] arteries and
peritubular capillaries [200 ×]). (C) Immunofluorescence study of infiltrating neutrophils (red) in Gr-1-stained sections (200 ×). Bar charts show the
results of semiquantitative scoring results (see Materials and methods). (D) Bar charts of serum levels of serum creatinine and urea. Data are
expressed as mean ± standard error of the mean (n = 7 to 10 mice per group). **P < 0.01 versus sham. †P < 0.05; ‡P < 0.01 versus CLP without
VT. HPF, high-power field.
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migration toward rhC5a in vitro. Similarly, preincuba-
tion of PMNs with VT in vitro was not sufficient to
reduce PMN migration toward PL fluid from PBS-trea-
ted septic mice (Additional file 3). Collectively, these
data suggest that VT does not affect PMN migration in
a direct fashion at the cellular level but that VT is suffi-
cient to attenuate PMN accumulation in vivo.
Vasculotide improves survival of septic mice
Lastly, we performed survival experiments, the bench-
mark of any successful treatment regimen in human
sepsis. C57BL6 mice received 50, 200, or 500 ng of VT
(or an equal volume of PBS) i.p. at 16 hours and 1 hour
prior to CLP or sham surgery and at 24 hours and 48
hours after surgery. As a result, only 15% of mice pre-
treated with either PBS or 50 ng of VT survived com-
pared with 55% and 40% in the 200 ng and 500 ng VT
groups, respectively. Pretreatment with 200 ng of VT, in
comparison with PBS, was significantly associated with
better outcome (hazard ratio 0.39, 95% confidence inter-
val 0.19 to 0.81; P < 0.001) (Figure 5A). Finally, we
tested whether delayed administration of VT improves
survival in early sepsis. Therefore, mice were subjected
to CLP first and then treated with 200 ng of VT i.p. at
2, 24, and 48 hours after surgery. As a result, 100% of
mice in the control group died whereas 36% of mice
survived after rescue treatment with 200 ng of VT
(hazard ratio 0.22, 95% confidence interval 0.06 to 0.83;
P < 0.05) (Figure 5B).
Discussion
In sepsis, there is a fine line between overwhelming the
offending pathogen and inflicting severe collateral
damage to the host. In particular, disseminated (that is,
systemic) endothelial activation/injury is a devastating
but common feature of the hosts’ (often disproportion-
ate) immune response. It is characterized by capillary
leakage with subsequent tissue edema, distributive
shock, and leukocyte infiltration of vital remote organs
[29,30]. Despite advances in understanding the crucial
role of the vasculature in sepsis pathophysiology, the
mainstay of treatment remainsn o n - s p e c i f i cs u p p o r t i v e
care [32]. Pharmacologic strategies aimed at specifically
strengthening the vascular barrier thus could offer resis-
tance to leakage-associated conditions, such as ALI,
AKI, and multiple organ dysfunction syndrome.
Since the original report by Witzenbichler and collea-
gues [11] in 2005, several studies have confirmed that
activation of the non-redundant and endothelial-specific
Tie2 receptor pathway by adenoviral overexpression of
its agonist ligand Angpt1 (AdAngpt1) is sufficient to
prevent endotoxemia-induced vascular leakage [8] and
subsequent AKI [9] and ALI [5] in rodents. In a clinical
scenario, however, systemic delivery of Angpt1 by using
viral vectors is not yet feasible, and this is due in part to
the acuity of the disease state and the fact that it would
take at least 2 to 3 days to reach the peak plasma con-
centration of Angpt1. Consistent with this notion,
Huang and colleagues [5] found that administration of
AdAngpt1 shortly after endotoxin exposure failed to
improve outcome. Moreover, all of the aforementioned
studies used LPS from a well-defined bacterial strain to
bring about the onset of sepsis, whereas in human sep-
sis, the pathogenic bacteria are often not known, and
mixed infections that involve both Gram-negative and
Gram-positive bacteria are common [33].
To circumvent these issues, we recently investigated
whether acute intravenous administration of the recom-
binant form of human Angpt1 protein could protect
against multiple organ dysfunction syndrome in a mur-
ine model of polymicrobial abdominal sepsis [6].
Although we could indeed reproduce most of the find-
ings pursued with virally delivered Angpt1, histologic
studies by Cho and colleagues [34] suggest that intrave-
nously administered native Angpt1, in addition to its
rather short protein half-life, might get stuck to macro-
vascular endothelial cells and probably does not reach
Figure 3 Vasculotide (VT) augments Tie2 signaling in vivo. Mice were pretreated with VT 200 ng intraperitoneally) or phosphate-buffered
saline at 16 hours and 1 hour prior to cecal ligation and puncture (CLP) or sham surgery, respectively. Kidney tissues were harvested at 18 hours
after CLP or sham treatment. (A) Immunofluorescence study of phosphorylated Tie2 (pTie2, red) within glomeruli (400 ×). (B) Bar charts showing
the results of semiquantitative scoring within the renal vasculature (see Materials and methods). Data are expressed as mean ± standard error of
the mean (n = 7 to 10 mice per group). **P < 0.01 versus sham. ‡P < 0.01 versus CLP without VT.
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Page 8 of 14Figure 4 Vasculotide (VT) suppresses cecal ligation and puncture (CLP)-induced upregulation of proinflammatory cytokines in vivo but
does not affect cytokine release from macrophages in vitro. (A) Mice were pretreated with VT (200 ng intraperitoneally) or phosphate-
buffered saline (PBS) at 16 hours and 1 hour prior to CLP or sham surgery, respectively. Levels of tumor necrosis factor-alpha (TNF-a), interleukin-
6 (IL-6), keratinocyte-derived chemokine/interleukin-8 homologue (KC), macrophage inflammatory protein-2 (MIP-2), and monocyte chemotactic
protein-1 (MCP-1) in serum and peritoneal lavage (PL) fluid samples at 18 hours after CLP or sham surgery were quantified by bead-based flow
cytometry or enzyme-linked immunosorbent assay (ELISA), respectively. Data are expressed as mean ± standard error of the mean (SEM) (n = 7
to 10 mice per group). *P < 0.05; **P < 0.01 versus sham. †P < 0.05; ‡P < 0.01 versus CLP without VT. (B) Mouse resident peritoneal
macrophages were obtained from untreated wild-type mice by PL. Cells were cultured in RPMI 1640/1% fetal calf serum (FCS), preincubated or
not with 25 or 100 ng/mL VT for 1 hour, and then stimulated with lipopolysaccharide (LPS) (10 ng/mL) for 4 hours. In some experiments,
peritoneal macrophages were preincubated with an sTie-2-Fc chimera (5 μg/mL) 30 minutes prior to the addition of VT. (A) MIP-2 and (B) KC
protein levels were analyzed in conditioned medium by specific ELISA. Results are expressed as the mean ± SEM from three independent
experiments performed in triplicate. *P < 0.001 versus unstimulated control.
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Page 9 of 14Figure 5 Vasculotide (VT) improves survival of septic mice. Kaplan-Meier curves with log-rank testing show the effect of VT on survival in
polymicrobial sepsis induced by cecal ligation and puncture (CLP). (A) Mice were pretreated with different dosages (50, 200, or 500 ng) of VT or
phosphate-buffered saline (PBS) intraperitoneally (control) at 16 hours and 1 hour prior to CLP and at 24 hours and 48 hours afterward. (B) Mice
were subjected to CLP first and then treated with 200 ng of VT or PBS intraperitoneally at 2, 24, and 48 hours after CLP. Sham animals
underwent the same procedure as CLP mice except for CLP and were treated with control buffer (PBS). CI, confidence interval; HR, hazard ratio.
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Page 10 of 14the microvasculature efficiently. Moreover, large-scale
production of recombinant Angpt1 is costly and is hin-
dered by the aggregation and insolubility of the protein.
Owing to these limitations, the recombinant form of
human Angpt1, though effective in mice, seems inap-
plicable for use in patients with sepsis.
In this proof-of-principle study, we could show for the
first time that VT, a novel PEG-clustered synthetic 7-
mer reported to activate Tie2 in endothelial cell culture
and to promote angiogenesis in experimental diabetic
ulcers, augments Tie2 activation in vivo and effectively
protects against sepsis-induced vascular leakage and leu-
kocyte transmigration in a clinically relevant murine
model of polymicrobial abdominal sepsis. VT-driven
effects were associated with significant improvements in
several biochemical parameters of acute kidney and liver
dysfunction. Most importantly, both pre- and post-treat-
ment with VT significantly reduced mortality. The survi-
val benefit seen with VT actually exceeded what we [6]
and others [11] reported for recombinant Angpt1. A
VT-like drug therefore may have great potential as a
vascular barrier-protective agent in human sepsis as well
as other conditions of acute vascular leakage and inflam-
matory endothelial dysfunction.
Increasing evidence suggests that Angpt1 attenuates
endothelial barrier dysfunction and subsequent organ
injury through multi-level effects on intracellular signal-
ing, cytoskeleton, and junction-related molecules
[10,23,35,36]. For example, operational Angpt1/Tie2 sig-
naling prevents endothelial cell apoptosis by activating
the phosphoinositol 3-kinase/Akt survival pathway
[34,37]. Moreover, Angpt1 decreases vascular permeabil-
ity through coordinated and opposite effects on the Rho
GTPases Rac1 and RhoA, which in turn restrict the num-
ber and size of gaps that form at endothelial cell junc-
tions in response to various leakage-inducing agents such
as bradykinine, thrombin, VEGF, or TNF-a [10,23,35].
David and colleagues [38] recently showed that VT like-
wise counteracts endothelial gap formation and hyper-
permeability induced by LPS or soluble mediators in
pulmonary microvascular endothelial cells in vitro.
In addition, there is well-founded evidence that
Angpt1 attenuates thrombin and VEGF-induced leuko-
cyte adhesion and transmigration by blocking the upre-
gulation of adhesion molecules ICAM-1, VCAM-1, and
E-selectin on human umbilical vein endothelial cells
[36,39]. Consistent with prior studies on Angpt1 overex-
pression in inflammatory models [6,7,9,11,40,41], the
preventative effect of VT on leukocyte extravasation was
associated with reduced expression of ICAM-1 and
VCAM-1 in the present study. Although some investiga-
tors have described a role for Angpt1 in regulating che-
motaxis and migration of human leukocytes [42-44],
results from our complementary in vitro experiments
suggest that VT is not sufficient to attenuate migratory
capacity of murine PMNs.
Furthermore, as in some of the aforementioned stu-
dies, VT treatment prevented the upregulation of
inflammatory cytokines and chemokines in serum and
PL fluid. PMs not only are the most prominent leuko-
cytes within the healthy peritoneal cavity but also play a
central role in recruitment of blood-derived neutrophils
in experimental peritonitis. Given that Angpt1 was
recently found to block LPS-induced TNF-a production
in macrophages specifically through Tie2 ligation [31],
we hypothesized that the expression of ICAM-1 and
VCAM-1 and subsequent PMN infiltration are regulated
by macrophage-derived mediators in a Tie2-dependent
fashion. Surprisingly, the release of various cytokines
from LPS-treated macrophages in vitro was virtually not
affected by VT whereas in vivo VT treatment led to a
significant reduction in serum and PL fluid levels. We
conclude that either VT can affect the proinflammatory
mediator release from macrophages in vivo indirectly via
activation of other cell types, which in turn can modu-
late PM responses, or these other cell types themselves
may be responsible for the production of proinflamma-
tory mediators during peritonitis. In the latter scenario,
peritoneal mesothelial cells seem to be the most likely
candidates as they have been shown to play a crucial
role in initiating and amplifying the early inflammatory
response to intra-abdominal infections [45]. However,
Tie2 expression by mesothelial cells has not been
reported yet. In summary, our findings suggest that VT
exerts a preferential effect on the vascular endothelium-
to which expression of Tie2 is largely limited.
Vascular barrier dysfunction has been shown to play
a critical role in the complex pathogenesis of AKI [46].
VT-treated mice were protected from septic AKI as
evidenced by preserved renal function parameters.
However, our renal compartment-specific findings
regarding adhesion molecule expression might
mechanistically be involved but not exclusively respon-
sible for the better organ function. In fact, the only
modest suppression of ICAM-1 and VCAM-1 suggests
that an improvement of other factors such as systemic
and intrarenal hemodynamics might be accountable for
the better renal outcome. Kim and colleagues [9]
reported recently that pretreatment with an engineered
variant of AdAng1 prevented the decrease in renal
blood flow while improving the glomerular filtration
rate in LPS-challenged mice.
Our preliminary studies to determine optimal VT dosing
for the CLP studies revealed a biphasic response as deter-
mined by survival experiments. While these results were
somewhat surprising, it was previously shown that high
doses of VT result in a suboptimal activation of Tie2
receptor activity in vitro and decreased biological efficacy
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Page 11 of 14in vivo [26]. Experiments conducted to address potential
reasons for this observation indicate that high concentra-
tions of VT likely result in inefficient clustering of the
Tie2 receptor monomers into high-order complexes [26].
Consistent with this notion, several published accounts
demonstrate improved Tie2 activation to relatively low
concentrations of Angpt1 versus higher concentrations in
the same experimental setting [42,43,47,48]. Our findings
emphasize, in the case of ligands directed at Tie2, the criti-
cal importance of not grossly oversaturating the system
and thus impacting the ligand-driven clustering of Tie2.
Furthermore, while every effort was made to deliver the
m o s te f f e c t i v ed o s eo fV T ,t h ed o s i n gi n t e r v a lw a sb a s e d
mainly on theoretical considerations. Preliminary experi-
ments in healthy mice have shown that VT, in its PEGy-
lated formulation, can sustain endothelial Tie2 activation
for up to 72 hours (data not shown). Optimizing dosing
intervals and treatment duration therefore could further
improve outcome in experimental sepsis.
Solvent controls (in this case, PBS) are widely accepted
in preclinical sepsis studies. While the most rigorous con-
trol for VT would have been a four-armed branched PEG
attached to a scrambled peptide, we have to point out that
these and similar controls have been examined previously
[25,26]. Moreover, a 10-kDa, four-armed PEG (VT back-
bone) plus a cysteine on each arm did not activate Tie2 or
improve outcome in murine endotoxemia [38].
Systemic exposure to LPS has been shown to sup-
press Tie2 protein abundance, Tie2 activation, and
downstream signaling in murine lungs [6,49,50]. David
and colleagues [38] recently demonstrated that the
decreased lung Tie2 protein abundance during murine
endotoxemia is overcome by increased activation of
the remaining Tie2 molecules when VT is given. In
the present study, we could essentially reproduce these
findings in kidneys from septic CLP mice, suggesting
that the loss of operational Tie2 signaling is a systemic
event that occurs across various sepsis etiologies. It is
noteworthy that VT was capable of augmenting Tie2
signaling through the remaining pool of receptors,
thereby preserving net flux through this signaling path-
way. However, it is possible that soluble Tie2, whose
shedding probably depends on sepsis severity, sca-
venges VT and thereby ameliorates its effects on the
vascular endothelium [51]. Thus, a likely therapeutic
limitation is that VT has to be administered before the
vascular damage is too grave to repair. In this regard,
we were surprised that delayed administration of VT,
as opposed to delayed transfection with AdAngpt1 [5],
was still efficient at reducing mortality in the present
study. Given these findings, it seems of utmost impor-
tance that VT be given as early as possible in order to
maximize protective signaling through the remaining
pool of Tie2 receptor molecules.
Conclusions
In summary, we provide proof of principle in support of
the efficacious use of PEGylated VT, a drug-like Tie2
receptor agonist, to activate Tie2 in vivo,c o u n t e r a c t
microvascular endothelial barrier dysfunction, improve
multiple organ functions, and reduce mortality in a
clinically relevant murine sepsis model. Further studies
are needed to pave the road for clinical applications of
this therapy concept.
Key messages
￿ Systemic administration of vasculotide (VT)
induced long-lasting Tie2 activation in vivo.
￿ VT protected against sepsis-induced vascular leak-
age and leukocyte transmigration.
￿ VT-driven effects were associated with significantly
improved organ function and reduced circulating
cytokine levels.
￿ Prophylactic as well as therapeutic VT treatment
reduced mortality in septic mice.
Additional material
Additional file 1: Vasculotide induces Tie2 posphorylation in the
kidney in vivo. A) Schematic of Vasculotide (VT): Four, eight amino acid
peptides (NH2-CHHHRHSF-COOH) are covalently attached via cysteine
and maleimide (denoted by X) to a 10 kDa, tetrameric polyethylene
oxide. VT uses a peg to provide better stability, half-life, and resistance to
immune reaction, but additionally, the 4-armed peg serves as a structural
scaffold that displays 4 binding peptides in a configuration that is ideal
for activating Tie2. The peptide (named T7) originally described by
Tournaire R, et al (Ref 25) was found to bind outside of the shared
Angpt1, Angpt2 ligand binding pocket and was thus not able to displace
the endogenous ligands. This peptide was selected due to its reported
high affinity and the desire to not displace endogenous ligands. In the
initial publication describing VT (Ref 26) it was shown that unlike native
Angpt1, VT is unable to bind integrins and activate associated
downstream pathways. In its PEGylated form, the circulating half-life of
VT appears to be around 24 hrs. B) Healthy mice (n = 3 per group) were
euthanized at 16 h and 34 h after Vasculotide pre-treatment (200 ng
Vasculotide i.p. at 0 h and 16 h). Mice (n = 3) injected with control buffer
(PBS) only served as baseline controls (0 h). Immunoprecipitation (IP) for
Tie2 and consecutive immunoblot (Blot) for phosphotyrosine (4G10) from
kidney homogenates. C) Densitometry of B) showing the intensities of
Tie2 tyrosine phosphorylation (pTyr/Tie2 ratio). Data are expressed as
means ± SEM (*P < 0.05).
Additional file 2: Effect of Vasculotide on liver dysfunction. Mice
were pre-treated with Vasculotide (VT, 200 ng i.p.) or PBS at -16 h, -1 h
prior to CLP or sham surgery. Blood samples were obtained at 18 hours
(n = 10 per group) after CLP or sham treatment, respectively. Bar charts
showing activity of A) aspartate aminotransferase (AST), and B) alanine
aminotransferase (ALT). Data are expressed as means ± SEM (n = 7-10
mice/group). *P < 0.05; **P < 0.01 versus sham. †P < 0.05; ‡P < 0.01
versus CLP w/o VT.
Additional file 3: Vasculotide does not affect migratory capacity of
PMN in vitro. A) Chemotaxis assessed by Transwell migration assays of
bone marrow-derived neutrophils elicited with 300 ml of PL pools
obtained at 18 h after surgery from seven to ten mice pre-treated with
Vasculotide (VT, 200 ng i.p.) or PBS at -16 h, -1 h prior to CLP or sham
surgery, respectively. B) Bone marrow-derived neutrophils were pre-
incubated with different concentration of VT for 1 h and thereafter used
for Transwell migration assays toward recombinant human C5a (50 ng/
ml). C) Bone marrow-derived neutrophils were pre-incubated with
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Page 12 of 14different concentration of VT for 1 h and thereafter used for Transwell
migration assays toward 300 ml of PL pools obtained at 18 h after CLP-
surgery. Data are presented as the percentage of PMN number loaded
into the upper chamber that had migrated to the bottom well, expressed
as means ± SEM (two independent experiments performed in duplicates).
*P < 0.05; **P < 0.01 vs. sham. †P < 0.05; ‡P < 0.01 vs. CLP w/o VT.
Abbreviations
AdAngpt1: agonist ligand angiopoietin-1; AKI: acute kidney injury; ALI: acute
lung injury; Angpt1: angiopoietin-1; Angpt2: angiopoietin-2; BSA: bovine
serum albumin; CLP: cecal ligation and puncture; ELISA: enzyme-linked
immunosorbent assay; FCS: fetal calf serum; ICAM-1: intercellular adhesion
molecule-1; IL-6: interleukin-6; i.p.: intraperitoneally; KC: keratinocyte
chemoattractant; LPS: lipopolysaccharide; MCP-1: macrophage
chemoattractant protein-1; MIP-2: macrophage inflammatory protein-2; PBS:
phosphate-buffered saline; PEG: polyethylene glycol; PL: peritoneal lavage;
PM: peritoneal macrophage; PMN: polymorphonuclear neutrophil; TNF-α:
tumor necrosis factor-alpha; VCAM-1: vascular cell adhesion molecule-1;
VEGF: vascular endothelial growth factor; VT: vasculotide.
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